Poster SESSIONS
51
Poster, 23 June 2014
Authors are asked to present their posters during the poster sessions.
P-05-009
Cariprazine demonstrates greater potency
than aripiprazole in animal models of psy-
chosis, cognitive impairment, and negative
symptoms
Nika Adham, Jersey City, USA
I. Gyertyan, B. Kiss
P-05-010
The outcome of acute transient psychotic
disorders according to 5-year follow-up
Galina Aleshkina, Moscow, Russia
L. Bardenshteyn, D. Murtazalieva
P-05-011
Prefrontal GABA modulation of working
memory processes
Meagan Auger, Vancouver, Canada
S. Floresco
P-05-012
Aripiprazole once-monthly for long-term
maintenance treatment of schizophrenia:
A 52-week open-label study
Ross Baker, Princeton, USA
T. Peters-Strickland, R. D. McQuade, N. Jin,
A. Eramo, P. P. Perry, B. R. Johnson, A. R. Duca,
R. Sanchez
P-05-013
Disrupted effective connectivity of emotional
circuitry in schizophrenia
Francesco Benedetti, Milan, Italy
B. Vai, G. Sferrazza Papa, S. Poletti, D. Radaelli,
R. Cavallaro, E. Smeraldi
P-05-014
Risk factors for new episode of schizophrenia
Alma Bravo-Mehmedbasic, Sarajevo, Bosnia
and Herzegovina
A. Kucukalic, A. Dzubur Kulenovic, J. Musabe-
govic
P-05-015
Efficacy and safety of adjunctive bitopertin
(10 and 20 mg) versus placebo in subjects
with sub-optimally controlled symptoms of
schizophrenia treated with antipsychotics –
results from the Phase III TwiLyte study
Dragana Bugarski-Kirola, Basel, Switzerland
W. W. Fleischhacker, T. Blaettler, C. J. Edgar, S.
Milosavljevic-Ristic, F. Lamour, S. Sun, S. Kapur
P-05-016
Minocycline add-on to haloperidol: Brain
topography of glutamatergic signaling
transcripts and implications for psychosis
treatment
Elisabetta Filomena Buonaguro, Naples, Italy
C. Tomasetti, F. Marmo, G. Latte, L. Avvisati,
F. Iasevoli, A. de Bartolomeis
P-05-017
Reduced expression of both brain-derived
neurotrophic factor and reelin sensitizes
to the long-term effects of glucocorticoid
stimulation on memory in mice: Relevance
to schizophrenia
Laetitia Buret, Melbourne, Australia
M. van den Buuse
P-05-018
Gender differences in the pharmacotherapy
of schizophrenia
Eva Ceskova, Brno, Czech Republic
R. Prikryl, J. Libiger
P-05-019
Genetic association between GRIA2, GRIA4
gene polymorphisms and clinical phenotypes
of schizophrenia
Seongwoo Cho, Seoul, Republic of Korea
W. S. Kang, Y. J. Kim, J. W. Kim
P-05-020
Association between promoter polymor-
phism (-1572T/C) in 5-hydroxytryptamine
receptor 3B and poor concentration in
schizophrenia
Seongwoo Cho, Seoul, Republic of Korea
H. J. Park, W. S. Kang, Y. J. Kim, J. W. Kim
P-05-021
Preference for long-acting injectable antipsy-
chotics of community-dwelling patients with
schizophrenia and their caregivers in Korea
In Won Chung, Goyang-Si, Gyeonggi-Do, Re-
public of Korea
Y.-S. Kim, N. Y. Lee, T. Youn
P-05-022
Metabolic syndrome in chronic antipsychotic
treatment of schizophrenia
In Won Chung, Goyang-Si, Gyeonggi-Do, Re-
public of Korea
N. Y. Lee, Y. S. Kim, T. Youn, S. H. Kim, U. G.
Kang, Y. M. Ahn
